Loading presentation…
Opening in Keynote for Mac...
Choose Media…
Your browser isn’t fully supported.
For the best Keynote for iCloud experience, use a supported browser.
Learn More
Cancel
Continue
Little additional information seems to be publicly
available right now:
Pfi zer and BioNTech
(2020-11-09):
Announce
Vaccine Candidate Against COVID-19 Achieved
Success in First Interim Analysis from Phase 3
Study
<
https://www.businesswire.com/news/home/
20201109005539/en/
>: ‘Vaccine candidate was
found to be more than 90
%
effective in preventing
COVID-19 in participants without evidence of prior
SARS-CoV-2 infection in the fi rst interim effi cacy
analysis. Analysis evaluated 94 confi rmed cases of
COVID-19 in trial participants. Study enrolled
43,538 participants, with 42
%
having diverse
backgrounds, and no serious safety concerns have
been observed; Safety and additional effi cacy data
continue to be collected. Submission for Emergency
Use Authorization (EUA) to the U.S. Food and
Drug Administration (FDA) planned for soon after
the required safety milestone is achieved, which is
currently expected to occur in the third week of
November. Clinical trial to continue through to fi nal
analysis at 164 confi rmed cases in order to collect
further data and characterize the vaccine
candidate’s performance against other study
endpoints…
BioNTech 90
%
Effective Messenger RNA COVID Vaccine?
Bojan Pancevski & Jared S. Hopkins
(2020-10-22):
How Pfi zer Partner BioNTech
Became a Leader in Coronavirus Vaccine
Race
_<
https://www.wsj.com/articles/how-pfi zer-
partner-biontech-became-a-leader-in-coronavirus-
vaccine-race-11603359015
>: ‘MAINZ, Germany—
On a Friday in late January, Ugur Sahin received an
email with bad news: A new study of a deadly new
coronavirus in China suggested it was more
infectious than previously believed. The outbreak,
he believed, had the potential to grow into a
pandemic. The following Monday, the German
scientist and chief executive of biotech fi rm
BioNTech SE summoned his board to announce
that the company, which had been developing next-
generation cancer treatments, would start work on a
Covid-19 vaccine. Human trials would need to start
by April, he added, in case Europe and the U.S. had
to go into lockdowns. Ugur Sahin, co-founder and
chief executive of BioNTech, led the company to
focus on coronavirus research early in the
pandemic. While much of the world was still
oblivious to the danger, BioNTech was scrambling,
Dr. Sahin told The Wall Street Journal earlier this
month…
BioNTech
: “
Our vaccine consists of a short
segment of
…
messenger RNA
…
provi
d[ing]
instructions for a human cell to make a harmless
version of a target protein,
…
which activates the
body’s immune response against the SARS-CoV-2
virus. We expect that our vaccination approach will
stimulate the immune system to generate protective
antibodies. This means the immune systems learns
how to recognize the SARS-CoV-2 virus upon
exposure and prevent subsequent infection. Unlike
other vaccines, mRNA vaccines do not contain the
virus itself and therefore pose no risk of infection
…
2020-11-09
<
https://www.businesswire.com/news/home/20201109005539/en/
>
<
https://www.icloud.com/keynote/0aP8gr2_cfSeHzTQEw9OVC6hg
> <
https://www.bradford-delong.com/2020/11/biontech-90-effective-messenger-rna-covid-vaccine.html
>
